Boston Partners cut its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 19.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 512,976 shares of the medical research company's stock after selling 124,947 shares during the period. Boston Partners owned about 0.09% of Amgen worth $216,142,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently made changes to their positions in AMGN. State Street Corp increased its position in shares of Amgen by 38.2% in the second quarter. State Street Corp now owns 42,205,243 shares of the medical research company's stock valued at $15,283,363,000 after acquiring an additional 11,656,755 shares during the period. Bank of America Corp DE purchased a new stake in shares of Amgen during the second quarter worth about $1,831,903,000. Wellington Management Group LLP boosted its holdings in shares of Amgen by 1,102.7% during the second quarter. Wellington Management Group LLP now owns 2,742,271 shares of the medical research company's stock worth $993,031,000 after purchasing an additional 2,514,254 shares during the period. BlackRock Inc. grew its stake in shares of Amgen by 4.8% in the second quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company's stock worth $17,874,974,000 after purchasing an additional 2,261,544 shares during the last quarter. Finally, Assenagon Asset Management S.A. increased its holdings in Amgen by 702.8% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,535,257 shares of the medical research company's stock valued at $647,126,000 after purchasing an additional 1,344,010 shares during the period. Institutional investors own 76.50% of the company's stock.
Amgen Price Performance
Shares of AMGN opened at $438.82 on Friday. The company has a debt-to-equity ratio of 3.60, a quick ratio of 1.20 and a current ratio of 1.48. The firm's 50-day simple moving average is $429.28 and its two-hundred day simple moving average is $383.32. Amgen Inc. has a fifty-two week low of $312.39 and a fifty-two week high of $483.99. The stock has a market cap of $237.36 billion, a PE ratio of 25.45, a price-to-earnings-growth ratio of 3.09 and a beta of 0.43.
Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings data on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share for the quarter, topping analysts' consensus estimates of $5.79 by $0.66. Amgen had a net margin of 24.14% and a return on equity of 114.99%. The company had revenue of $10.37 billion during the quarter, compared to analyst estimates of $10.07 billion. During the same period in the previous year, the business earned $5.64 EPS. The firm's revenue for the quarter was up 8.5% on a year-over-year basis. Analysts anticipate that Amgen Inc. will post 23.37 earnings per share for the current fiscal year.
Amgen Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Friday, December 11th. Shareholders of record on Friday, November 20th will be issued a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, November 20th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.3%. Amgen's dividend payout ratio is presently 58.47%.
Wall Street Analysts Forecast Growth
AMGN has been the topic of a number of recent analyst reports. Guggenheim lifted their price objective on Amgen from $378.00 to $435.00 and gave the stock a "neutral" rating in a research report on Thursday, November 5th. BMO Capital Markets dropped their price target on Amgen from $450.00 to $415.00 and set a "market perform" rating for the company in a research note on Monday, October 12th. Citigroup lifted their price target on shares of Amgen from $405.00 to $465.00 and gave the company a "neutral" rating in a report on Wednesday, November 4th. Scotiabank boosted their price objective on shares of Amgen from $500.00 to $530.00 and gave the company a "sector outperform" rating in a research report on Wednesday, November 4th. Finally, Bank of America upped their price objective on shares of Amgen from $312.00 to $317.00 and gave the stock an "underperform" rating in a report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, eighteen have given a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Amgen presently has an average rating of "Hold" and a consensus target price of $428.62.
View Our Latest Research Report on Amgen
About Amgen
(
Free Report)
Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company's medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.
Featured Articles
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Amgen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.
While Amgen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.